HC Wainwright Reaffirms “Buy” Rating for UroGen Pharma (NASDAQ:URGN)

HC Wainwright reaffirmed their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a report published on Monday morning, Benzinga reports. The firm currently has a $60.00 price objective on the stock. HC Wainwright also issued estimates for UroGen Pharma’s Q2 2024 earnings at ($0.77) EPS, Q3 2024 earnings at ($0.75) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($3.16) EPS, Q1 2025 earnings at ($0.75) EPS, Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.61) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.72) EPS.

A number of other equities research analysts have also recently weighed in on the company. LADENBURG THALM/SH SH upped their price target on UroGen Pharma from $48.00 to $53.50 and gave the stock a buy rating in a report on Friday, June 14th. Oppenheimer increased their target price on UroGen Pharma from $32.00 to $40.00 and gave the company an outperform rating in a report on Friday, June 14th.

UroGen Pharma Price Performance

URGN opened at $15.01 on Monday. The stock has a market cap of $351.98 million, a P/E ratio of -4.41 and a beta of 1.12. The stock’s 50 day simple moving average is $14.42 and its 200 day simple moving average is $15.26. UroGen Pharma has a 1-year low of $8.69 and a 1-year high of $24.13.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.04). The company had revenue of $18.78 million during the quarter, compared to analyst estimates of $20.73 million. Research analysts expect that UroGen Pharma will post -3.6 EPS for the current fiscal year.

Insider Buying and Selling at UroGen Pharma

In other UroGen Pharma news, insider Mark Schoenberg sold 5,153 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $13.08, for a total transaction of $67,401.24. Following the sale, the insider now owns 144,284 shares in the company, valued at approximately $1,887,234.72. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in URGN. China Universal Asset Management Co. Ltd. lifted its stake in shares of UroGen Pharma by 361.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,575 shares of the company’s stock worth $54,000 after purchasing an additional 2,801 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of UroGen Pharma by 31.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 4,955 shares of the company’s stock worth $74,000 after purchasing an additional 1,191 shares during the period. SG Americas Securities LLC purchased a new position in shares of UroGen Pharma during the 4th quarter worth $131,000. Federated Hermes Inc. purchased a new position in shares of UroGen Pharma during the 3rd quarter worth $184,000. Finally, Sierra Summit Advisors LLC purchased a new position in shares of UroGen Pharma during the 4th quarter worth $218,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.